Edesa Biotech, Inc. (EDSA) Form 424B5 — Aug 20, 2026
Edesa Biotech (EDSA) priced a $25.0 million underwritten offering of 3,870,500 common shares at $5.50 per share-and-warrant unit, below the $5.75 Nasdaq close on August 19, 2026, with Guggenheim Securities as sole book-running manager. Certain investors received pre-funded warrants for up to 675,000 shares in lieu of shares, and every unit includes a warrant to purchase one share at $7.50. Net proceeds are expected to be approximately $23.1 million, rising to approximately $26.6 million if Guggenheim exercises its 30-day option for up to 681,825 additional units in full.
Key figures
- Gross Proceeds
- 25000182.5
- Offering Price
- 5.5
- Shares Offered
- 3870500
- Shares Outstanding
- 13503723
- Lockup Period
- 90 days (company and officers/directors)
- Warrant Expiration
- earlier of 18-month anniversary of issuance or 30 days after public announcement of Phase 2 vitiligo topline data for EB06
- Expected Closing Date
- on or about August 21, 2026
- Expected Net Proceeds
- approximately $23.1 million ($26.6 million if greenshoe exercised in full)
- Atm Remaining Capacity
- 2262508
- Warrant Exercise Price
- 7.5
- Pre Funded Warrant Shares
- 675000
- Net Tangible Book Value Pre
- approximately $6.9 million, or $0.72 per share
- Estimated Offering Expenses
- approximately $300,000
- Immediate Dilution Per Share
- 3.28
- Pre Funded Warrant Unit Price
- 5.4999
- Underwriting Discount Total
- 1500015
- Common Share Warrants Offered
- 4545500
- Greenshoe Shares And Warrants
- 681825
- Last Reported Sale Price Aug19
- 5.75
- Underwriting Discount Per Unit
- 0.33
- Shares Outstanding Pre Offering
- 9633223
- Pre Funded Warrant Exercise Price
- 0.0001
- As Adjusted Net Tangible Book Value
- approximately $30.0 million, or $2.22 per share
- Underwriter Expense Reimbursement Cap
- 150000
- Warrant Exercise Fee To Representative
- 6% of gross proceeds on warrant exercises
Price after filing
Close on the filing date to close N calendar days later (from $4.76). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.